DENALI THERAPEUTICS INC - ROYALTY PHARMA TO RECEIVE 9.25% ROYALTY ON WORLDWIDE SALES OF TIVIDENOFUSP ALFA FROM DENALI

Reuters · 2d ago

Please log in to view news